Publications
May 15, 2025
Improve Lives, Prevent Deaths: Guide for Community Organizations & Policymakers with Actionable Strategies for Preventing Overdose
Overdose deaths and opioid use disorder continue to affect people in Washington State. Communities have made significant efforts to address this issue, but building a comprehensive and successful approach can be challenging. Fortunately, there is strong evidence about which strategies are most likely to be effective. A comprehensive response braids multiple strategies to develop holistic…
May 14, 2025
New ADAI Report: Assessing Engagement in Cannabis Policy: A Survey of Washington State Elected Officials
In 2012, Washington State passed Initiative 502, establishing a comprehensive regulatory framework for cannabis. This initiative allowed the state to license growers, processors, and retail stores. The Washington State Liquor and Cannabis Board (LCB) handles licensing and regulation, while the state legislature makes cannabis laws. Local governments, like cities and counties, can also make their…
May 9, 2025
New Publications from ADAI: Contingency management, the fentanyl epidemic, suicide prevention for Native youth, Permanent Supportive Housing, Prenatal alcohol exposure
Check out the latest publications from ADAI faculty: Centering peers in design and training for a peer-delivered contingency management program for self-identified harm reduction and treatment goals.Peng L, Stack E, Cooke A, Hartzler B, et al.Harm Reduction Journal 2025;22(suppl 1):72. This study tested a new way to help people who use stimulants get support and…
April 11, 2025
New Guide: Supporting the Health of Youth Who Use Fentanyl/Opioids: Information for Family & Friends
The ADAI Center for Community-Engaged Drug Education, Epidemiology & Research (CEDEER) is happy to announce the release of the new guide Supporting the Health of Youth Who Use Fentanyl/Opioids: Information for Family and Friends. This guide is available online and as a printable 12-page pamphlet from CEDEER’s website LearnAboutTreatment.org. It focuses on two key ideas,…
January 16, 2025
CTN Pacific NW Node at ADAI: Outcomes Papers for Study on PrEP in High-HIV-Incidence Southern U.S. Cities
The Pacific Northwest Node of the NIDA Clinical Trials Network, directed by Mary Hatch, PhD (UW ADAI), and John Roll, PhD (WSU), had a very productive 2024, with 4 published papers and 4 more in the works! (Need help getting copies of the published papers below? Contact ADAI librarian Meg Brunner: meganw@uw.edu.) New Publications First, they recently participated in…
December 18, 2024
New ADAI Articles: Pharmacy Staff and Naloxone & PReP Use by MSM Who Use Substances
Two new papers by ADAI researchers and colleagues are now available! Pharmacy staff-reported adaptations to naloxone provision and over-the-counter (OTC) syringe sales during the COVID-19 pandemic: Experiences across multiple states and 2 pharmacy chains. Green TC, Silcox J, Bolivar D, Gray M, Floyd AS, et al. J Amer Pharm Assoc 2024;64(1):71-78. [subscription access] This paper…
November 14, 2024
New from CERP Director Beatriz Carlini: Report & Recommendations of the High Potency Cannabis Think Tank to the State of California
ADAI’s Cannabis Education & Research Program Director Beatriz Carlini, PhD, MPH is one of the co-authors of a new report: “Report and Recommendations of the High Potency Cannabis Think Tank to the State of California.” This report was prepared by a committee of scientists (including Dr. Carlini) and medical experts convened by the California Department…
September 20, 2024
New ADAI Research: Community-Based Medications First for Opioid Use Disorder
Citation: Banta-Green CJ, Owens MD, Williams JR, Floyd AS, Williams-Gilbert W, Kingston S. Community-based medications first for opioid use disorder – Care utilization and mortality outcomes. Substance Abuse and Rehabilitation 2024;15:173-183. The most effective and evidence-based treatments for opioid use disorder (OUD) are medications for OUD (MOUD) like buprenorphine, methadone, and extended-release injectable naltrexone. However,…
September 17, 2024
WA State Drug Brief: BTMPS: New Substance Found in Community Drug Checking Samples
In June 2024, a new substance, Bis(2,2,6,6-tetramethyl-4-piperidyl) sebacate (BTMPS), was detected in the unregulated drug supply nationally in community drug testing programs, most commonly in products sold as and containing fentanyl. BTMPS is an industrial chemical with no approved use in humans. The effects of the substance and why it might be in the drug…
September 16, 2024
New ADAI Publication: Substance Use Disorder Training for WA State Basic Law Enforcement Academy
Citation: Owens MD, et al. Development and exploratory evaluation of substance use and substance use disorder training for the Washington State Basic Law Enforcement Academy. Policing 2024;18:paae091. In 2021, Washington State passed a law requiring all new law enforcement officers to get training on substance use disorder (SUD), with a goal of improving conflict resolution…
Next page
